eRAPID Electronic patient self-Reporting of Adverse-events: Patient Information and aDvice: randomised controlled trial in systemic cancer treatment
- Conditions
- Colorectal cancer, breast cancer, cervical cancer, ovarian cancer, rectal cancer or uterine cancerCancer
- Registration Number
- ISRCTN88520246
- Lead Sponsor
- niversity of Leeds (UK)
- Brief Summary
2017 protocol in: https://www.ncbi.nlm.nih.gov/pubmed/28482877 2021 results in https://pubmed.ncbi.nlm.nih.gov/33417506/ (added 11/01/2021)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 508
1. Adult patients (aged 18 years or over) attending St James? University Hospital diagnosed with early breast or colorectal cancer requiring adjuvant systemic treatment, or gynaecological cancer requiring chemotherapy (recruitment may be extended in the main trial to include testicular cancer patients receiving systemic therapy)
2. Prescribed at least three months of planned chemotherapy cycles at the time of study consent
3. Able and willing to give informed consent
4. Able to read and understand English
5. Access to the internet at home
Patients who are:
1. Taking part in other clinical trials involving the completion of extensive patient reported outcome or quality of life measures
2. Exhibiting overt psychopathology/cognitive dysfunction
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical outcomes and process of care measures; Timepoint(s): Throughout 18 week study period
- Secondary Outcome Measures
Name Time Method <br> 1. Costs to patients and the NHS; Timepoint(s): Throughout 18 week study period<br> 2. Patient-reported outcomes; Timepoint(s): Baseline, 6, 12, 18 weeks<br>